HACKENSACK, N.J. and PETACH TIKVAH, Israel, Aug. 14, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced financial results for the second quarter ending June 30, 2017.
“We are in the advanced stages of preparing for our pivotal Phase 3 trial to investigate NurOwn® in ALS,” said Chaim Lebovits, President and Chief Executive Officer of BrainStorm.
